Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met. Data as of 17/09/2026.
- ❌ Price trend failed
- ❌ Growth failed
- ❌ Debt failed
- ✅ P/E passed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2021 → 2022: -8.28%
Price change 2022 → 2023: -48.37%
Price change 2023 → 2024: 3.47%
Price change 2024 → 2025: -51.94%
Price change 2025 → 2026: 88.98%
Price change 2026 (year to date): 87.15%
Financial growth
Revenue CAGR (8 years): -6.27%
Earnings CAGR (8 years): -29.47%
Growth status: weak or negative trend (<1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 11.70
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 4.10
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 0.07% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="OGN" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Organon & Co. | 4.2 | 11.70 | −6.3 % | 🔒 |
| AbCellera Biologics Inc. | – | 0.15 | +35.8 % | – |
| Tecan Group AG | – | 0.19 | +6.0 % | – |
| Carl Zeiss Meditec AG | 23.1 | 0.29 | +8.3 % | – |
| Fielmann AG | 13.8 | 0.90 | +6.2 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Organon & Co. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 6.5 bn | 2.2 bn | 33.1 % | n/a |
| 2021 | 6.3 bn | 1.4 bn | 21.4 % | -3.5 % |
| 2022 | 6.2 bn | 917 m | 14.8 % | -2.1 % |
| 2023 | 6.3 bn | 1.0 bn | 16.3 % | +1.4 % |
| 2024 | 6.4 bn | 864 m | 13.5 % | +2.2 % |
| 2025 | 6.2 bn | 187 m | 3.0 % | -2.9 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Valuation and competitors
Organon & Co. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Organon & Co. | 3.7 bn | 4.2 | 3.0 % |
| Phibro Animal Health Corporation PAHC | 1.5 bn | 12.3 | 3.7 % |
| Aurinia Pharmaceuticals Inc. AUPH | 2.1 bn | 15.4 | 101.5 % |
| Nuvation Bio Inc. NUVB | 1.4 bn | n/a | -325.3 % |
| Tilray Brands, Inc. TLRY | 272 m | n/a | -266.2 % |
| Harmony Biosciences Holdings, Inc. HRMY | 2.0 bn | 11.0 | 18.3 % |
| Pediatrix Medical Group, Inc. MD | 2.4 bn | 14.0 | 8.6 % |
| Guardian Pharmacy Services, Inc. GRDN | 3.1 bn | 43.4 | 3.4 % |
| Sector median (NYSE) | 27.7 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Organon & Co. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 7 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Organon & Co.
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| BlackRock | 32.1 m | 434 m | 0.0 % | +1.1 % | 2026Q2 |
| Vanguard Group | 36.9 m | 265 m | 0.0 % | +2.7 % | 2025Q4 |
| State Street | 19.3 m | 262 m | 0.0 % | +94.0 % | 2026Q2 |
| Goldman Sachs | 5.2 m | 70.4 m | 0.0 % | +223.9 % | 2026Q2 |
| Geode Capital Management | 4.8 m | 65.2 m | 0.0 % | +1.2 % | 2026Q2 |
| Millennium Management | 3.4 m | 46.6 m | 0.0 % | -49.2 % | 2026Q2 |
| Morgan Stanley | 2.2 m | 29.8 m | 0.0 % | -33.1 % | 2026Q2 |
| Northern Trust | 2.1 m | 28.2 m | 0.0 % | +8.7 % | 2026Q2 |
Latest insider transactions
| Date | Person | Side | Amount |
|---|---|---|---|
| 05/08/2026 | Drinane Juliana Papa | sale | 200,307 USD |
Elected officials' disclosures
| Date | Official | Side | Amount |
|---|---|---|---|
| 05/08/2026 | Kevin Hern | sale | $1,001 - $15,000 |
| 05/08/2026 | Kevin Hern | sale | $1,001 - $15,000 |
| 10/07/2025 | Gary C. Peters | sale | $1,001 - $15,000 |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Organon & Co.
What is the Organon & Co. share price?
Latest recorded price: 13.90 USD on 13/11/2026, for a market cap of 3.7 bn USD.
What is the revenue of Organon & Co.?
6.2 bn USD for fiscal year 2025, with net income of 187 m USD (net margin 3.0 %).
What do analysts say about Organon & Co.?
Out of 9 analysts: 2 buy or strong buy, 4 hold, 3 sell or strong sell.
What is the P/E ratio of Organon & Co.?
Trailing 12-month P/E of 4.2, against 27.7 for the sector median on the same exchange (10-year median: 22.3).
Is Organon & Co. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US68622V1061).
How many employees does Organon & Co. have?
10,000 full-time employees according to the latest published profile.
Who runs Organon & Co.?
Kevin Ali is the company's chief executive.
Which large funds own Organon & Co.?
As of 2026Q2, among the large funds tracked: BlackRock, Vanguard Group, State Street, Goldman Sachs, Geode Capital Management.